20/20 OptimEyes Technologies recognized as the 2025 Blue Ticket Competition winner

OBIO NewsOntario Industry Updates
Written By Arsheen Kaur

University of Toronto Mississauga’s SpinUp and Merck recently announced 20/20 OptimEyes Technologies as the winner of the 2025 Blue Ticket Competition. The program, now in its second year, supports breakthrough innovation in life sciences.

20/20 OptimEyes Technologies is the recipient of:

  • A free one-year membership at SpinUp, U of T’s first wet lab startup incubator at the University of Toronto Mississauga (UTM) campus

  • Mentorship and guidance from seasoned Merck scientists and business leaders

  • Access and support from U of T’s research talent and network.

20/20 OptimEyes Technologies is an OBIO® member, an alumnus of our BDSP™, CAAP® and HealthMINT® programs, and presented at the OBIO® Investment Summit.

Read more
Arsheen Kaur
Previous

Supply Ontario and OBIO® to drive procurement of Canadian-made innovative healthcare solutions
Next

ProteinQure announced first patient dosed in Phase I clinical trial of PQ203 in advanced metastatic cancer